Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Vermont has the second lowest state fatality rate in the US (148.4 per 100K; Hawaii 113.7/100K). Mississippi (466/100K) and ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

Researchers divided US registry data from the National Cancer Database into derivation and validation cohorts in order to reappraise HPV-positive oropharyngeal carcinoma pathological staging.

A recent study linking human pegivirus to Parkinson’s is leading scientists to examine the connection between other viral ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

Vicebio, a biopharmaceutical company that develops vaccines for serious respiratory viral infections, has agreed to be ...